IP Library Granted Patent US 8,481,575
Granted Patent B2
US 8,481,575 · App. 13/040,211 · Granted Jul 9, 2013

Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Inventors: Samuel J. Danishefsky (Englewood, NJ); Peter Bertinato (Old Lyme, CT); Dai-shi Su (Dresher, PA); Dongfang Meng (Westfield, NJ); Ting-Chao Chou (Paramus, NJ); Ted Kamenecka (San Diego, CA); Erik J. Sorensen (Princeton, NJ); Aaron Balog (Lambertville, NJ); Kenneth A. Savin (Indianapolis, IN)
Assignee: Sloan-Kettering Institute for Cancer Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,481,575
App. No.
13/040,211
Granted
Jul 9, 2013
Kind
B2
Abstract

The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof. Also provided are analogues related to epothilone A and B and intermediates useful for preparing same. The present invention further provides novel compositions based on analogues of the epothilones and methods for the treatment of cancer and cancer which has developed a multidrug-resistant phenotype.

Claims (10)

1. A method of stabilizing microtubules in a subject, the method comprising steps of:

administering to a subject in need thereof a composition comprising a compound having the structure:

wherein:

R 1 is H or methyl;

according to an administration schedule that delivers to the subject a dose that corresponds to an average daily dose in a mouse that is within the range of 0.001-25 mg/kg.

2. The method of claim 1 , wherein the administration schedule that delivers to the subject a dose that corresponds to an average daily dose in a mouse that is within the range of 0.001-10 mg/kg.

3. The method of claim 1 , wherein the administration schedule that delivers to the subject a dose that corresponds to an average daily dose in a mouse that is within the range of 0.001-1.0 mg/kg.

4. The method of claim 1 , wherein in the compound R 1 is H.

5. The method of claim 1 , wherein in the compound R 1 is methyl.

6. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier selected from the group consisting of glycols, oils, and alcohols.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jun 29, 2016
From: SLOAN-KETTERING INST CAN RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039204/0286 →
Continuity (17)
Continuation 12790064 · May 28, 2010
Continuation 11652383 · Jan 11, 2007
Continuation 10695582 · Oct 28, 2003
Continuation 10431467 · May 7, 2003
Continuation 10374805 · Feb 25, 2003
Continuation 10058695 · Jan 28, 2002
Continuation 10004571 · Dec 4, 2001
Continuation 09874514 · Jun 5, 2001
Continuation 09808451 · Mar 13, 2001
Continuation 09691615 · Oct 18, 2000
Continuation 08986025 · Dec 3, 1997
Provisional Application 60032282 · Dec 3, 1996
Provisional Application 60033767 · Jan 14, 1997
Provisional Application 60047566 · May 22, 1997
Provisional Application 60047941 · May 29, 1997
Provisional Application 60055533 · Aug 13, 1997
Related Publication 20110263663A1 · Oct 27, 2011